Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiarrhythmic Drugs.

Steven N. Singh1, Jonathan Patrick, Jonathan Patrick

  • 1VA Medical Center, Cardiology, 50 Irving Street, NW, Room 1E301, Washington, DC 20422, USA. steve.singh@med.va.gov

Current Treatment Options in Cardiovascular Medicine
|August 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advance Multi-Priority, Multi-Appointment Patient Scheduling With Dependent Demand and Lead Times.

Production and operations management·2026
Same author

Staff scheduling for residential care under pandemic conditions: The case of COVID-19.

Omega·2022
Same author

Developing the Pathologists' Monthly Assignment Schedule: A Case Study at the Division of Anatomical Pathology of The Ottawa Hospital.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2016
Same author

Using data envelopment analysis for assessing the performance of pediatric emergency department physicians.

Health care management science·2015
Same author

Evaluating emergency physicians: data envelopment analysis approach.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2014
Same author

Needs of people with dementia in long-term care: a systematic review.

American journal of Alzheimer's disease and other dementias·2013

Beta blockers are the only antiarrhythmic drugs proven to reduce sudden cardiac death, particularly in heart failure patients. Other antiarrhythmics may worsen arrhythmias, requiring careful patient selection.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Supraventricular and ventricular arrhythmias increase mortality and morbidity.
  • Antiarrhythmic drugs target cardiac ionic channels to manage arrhythmias.
  • Limited antiarrhythmic agents demonstrate mortality benefits.

Purpose of the Study:

  • To review the efficacy and safety of antiarrhythmic agents.
  • To provide guidelines for antiarrhythmic drug selection in specific patient populations.
  • To discuss the role of antiarrhythmics in ventricular arrhythmias.

Main Methods:

  • Literature review of antiarrhythmic drug therapies.
  • Analysis of clinical trial data on antiarrhythmic efficacy.
  • Guideline development based on evidence for specific arrhythmias and patient conditions.

Related Experiment Videos

Main Results:

  • Beta blockers are the only antiarrhythmics shown to reduce sudden arrhythmic death, especially post-myocardial infarction or in heart failure.
  • Specific drug recommendations are provided for atrial fibrillation/flutter conversion and maintenance based on structural heart disease.
  • Amiodarone, dofetilide, or dl-sotalol are preferred in structural heart disease; dofetilide or amiodarone in heart failure.
  • Antiarrhythmic therapy for ventricular arrhythmias is often questionable and potentially contraindicated, with beta blockers as an exception.
  • Implantable cardioverter-defibrillators and amiodarone may be considered for high-risk ventricular arrhythmia patients.

Conclusions:

  • Beta blockers offer significant mortality benefits in specific cardiac conditions.
  • Careful selection of antiarrhythmic agents is crucial, considering underlying heart disease and potential for proarrhythmia.
  • The role of antiarrhythmics in ventricular arrhythmias remains limited, emphasizing risk-benefit assessment.